EMA Authorised: Lucentis (ranibizumab) — Novartis Europharm Limited

View source ↗

Summary

EMA authorised Lucentis (ranibizumab) for multiple ophthalmic indications including wet age-related macular degeneration, macular edema, diabetic retinopathy, p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Diabetic Retinopathy
• Macular Edema
• Pathologic Myopia
• Wet Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization. MAH: Novartis Europharm Limited. Decision date: 16/12/2025